Seoulin Bioscience Co.Ltd (038070) - Total Liabilities

Latest as of September 2025: ₩27.16 Billion KRW ≈ $18.40 Million USD

Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) has total liabilities worth ₩27.16 Billion KRW (≈ $18.40 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Seoulin Bioscience Co.Ltd to assess how effectively this company generates cash.

Seoulin Bioscience Co.Ltd - Total Liabilities Trend (2013–2024)

This chart illustrates how Seoulin Bioscience Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Seoulin Bioscience Co.Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Seoulin Bioscience Co.Ltd Competitors by Total Liabilities

The table below lists competitors of Seoulin Bioscience Co.Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Milux Corporation Bhd KLSE:7935	Malaysia	RM30.37 Million
Canacol Energy Ltd. TO:CNE	Canada	CA$906.82 Million
New Century Logistics (BVI) Limited Ordinary Shares NASDAQ:NCEW	USA	$1.19 Million
OCR Group Bhd KLSE:7071	Malaysia	RM419.46 Million
HUBLine Bhd KLSE:7013	Malaysia	RM227.50 Million
PT Sarimelati Kencana Tbk JK:PZZA	Indonesia	Rp894.63 Billion
Redwood Group Ltd TWO:8426	Taiwan	NT$1.19 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Seoulin Bioscience Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Seoulin Bioscience Co.Ltd (038070) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.57	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.32	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Seoulin Bioscience Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Seoulin Bioscience Co.Ltd (2013–2024)

The table below shows the annual total liabilities of Seoulin Bioscience Co.Ltd from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩17.63 Billion ≈ $11.95 Million	-43.19%
2023-12-31	₩31.04 Billion ≈ $21.03 Million	-39.24%
2022-12-31	₩51.08 Billion ≈ $34.62 Million	-17.21%
2021-12-31	₩61.71 Billion ≈ $41.82 Million	+236.70%
2020-12-31	₩18.33 Billion ≈ $12.42 Million	-12.73%
2019-12-31	₩21.00 Billion ≈ $14.23 Million	+20.72%
2018-12-31	₩17.39 Billion ≈ $11.79 Million	-11.00%
2017-12-31	₩19.54 Billion ≈ $13.24 Million	+9.39%
2016-12-31	₩17.87 Billion ≈ $12.11 Million	-14.12%
2015-12-31	₩20.80 Billion ≈ $14.10 Million	+18.36%
2014-12-31	₩17.57 Billion ≈ $11.91 Million	-6.62%
2013-12-31	₩18.82 Billion ≈ $12.75 Million	--

About Seoulin Bioscience Co.Ltd

KQ:038070 Korea Biotechnology

Market Cap

$37.75 Million

₩55.70 Billion KRW

Market Cap Rank

#22893 Global

#1589 in Korea

Share Price

₩6310.00

Change (1 day)

-0.47%

52-Week Range

₩6050.00 - ₩8390.00

All Time High

₩36786.63